Investigational Drug Information for Arbaclofen placarbil

What is the development status for investigational drug Arbaclofen placarbil?

Arbaclofen placarbil is an investigational drug.

There have been 6 clinical trials for Arbaclofen placarbil. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1^st 2011.

The most common disease conditions in clinical trials are Gastroesophageal Reflux, Alcohol Drinking, and Sclerosis. The leading clinical trial sponsors are Indivior Inc., XenoPort, Inc., and [disabled in preview].

Summary for Arbaclofen placarbil

US Patents	0
International Patents	0
US Patent Applications	112
WIPO Patent Applications	37
Japanese Patent Applications	10
Clinical Trial Progress	Phase 3 (2011-05-01)
Vendors	23

Recent Clinical Trials for Arbaclofen placarbil

Title	Sponsor	Phase
A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers	Indivior Inc.	Phase 1
A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder	Indivior Inc.	Phase 2
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis	Indivior Inc.	Phase 3

See all Arbaclofen placarbil clinical trials

Clinical Trial Summary for Arbaclofen placarbil

Top disease conditions for Arbaclofen placarbil

Top clinical trial sponsors for Arbaclofen placarbil

See all Arbaclofen placarbil clinical trials

US Patents for Arbaclofen placarbil

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration

Development update and market projection for Arbaclofen Placarbil

Last updated: February 17, 2026

Overview

Arbaclofen placarbil is a prodrug of arbaclofen, designed to provide sustained GABA_B receptor agonist activity. Originally developed for neurological and gastrointestinal indications, it has undergone various clinical trials but has yet to gain regulatory approval. Key recent developments, current market considerations, and projections are reviewed below.

Development Progress

• Phase and Clinical Trials: Arbaclofen placarbil has advanced through Phase 2 trials targeting conditions like spasticity, alcohol dependence, and epilepsy. No recent Phase 3 data have been released publicly [1].

• Regulatory Status: The drug has not received FDA approval nor cleared EMA authorization. Multiple setbacks in demonstrating efficacy or safety have stalled commercialization prospects [2].

• Trial Outcomes:

  • Spasticity: Phase 2 results showed some improvement but failed to meet primary endpoints consistently.
  • Alcohol Dependence: Mixed efficacy signals; the trials encountered issues with patient adherence and placebo effects.
  • Gastrointestinal Motility: Limited data suggest potential, but development has not advanced.

• Partnerships and Licensing: Several pharmaceutical partnerships—by Solco Healthcare, Janssen, and others—have been announced, with limited success. No recent licensing deals are known publicly [3].

• Current Status: The developer, Solco Healthcare, as of late 2022, has not announced ongoing clinical trials, indicating possible discontinuation or strategic pause.

Market Projection

• Historical Market Context:

  • The GABAergic therapy space includes drugs like baclofen, gabapentin, and phenibut, with established uses in spasticity and epilepsy.
  • The neuropsychiatric market for alcohol dependence includes drugs such as naltrexone and acamprosate, with combined global sales exceeding $2 billion annually.

• Potential Indications:

  • Spasticity: Competitive landscape dominated by baclofen and tizanidine. Entry barriers include proven efficacy and safety.
  • Alcohol Dependence: Existing treatments have limited efficacy. A niche could open if Arbaclofen placarbil demonstrates superior safety or tolerability.
  • Gastrointestinal Disorders: Limited unmet medical need with current marketed therapies.

• Market Size and Revenue Estimates:	Indication	Estimated Global Market (2023)	Key Competitors	Barriers
  Spasticity	$3.2 billion	Baclofen, tizanidine	Established efficacy, safety profile
  Alcohol Dependence	$2.1 billion	Naltrexone, acamprosate	Existing drugs with proven track record
  G.I. Motility	$1.8 billion	Motilium, prucalopride	Market dominance by existing drugs

• Market Entry Feasibility:

  • Pending efficacy demonstration and safety profile improvements
  • Need for targeted clinical development and regulatory approvals
  • Competitive barriers stay high due to existing therapies

Forecast Scenario Analysis

• Best-Case Scenario (If new data show significant efficacy):

  • Regulatory approval within 3-5 years
  • Market penetration through strategic partnerships
  • Potential peak sales around $500 million annually within 7 years

• Base-Case Scenario:

  • Limited adoption due to competitive landscape
  • Slow growth with peak sales below $100 million
  • Development costs and regulatory hurdles limit profitability

• Worst-Case Scenario:

  • Discontinuation of development
  • No commercial sales
  • Minimal market impact

Conclusion

Arbaclofen placarbil faces significant hurdles from clinical, regulatory, and competitive standpoints. Its future largely hinges on new, compelling clinical data demonstrating clear benefits over existing therapies. Without such data, commercialization prospects remain low, and the compound is unlikely to contribute meaningfully to the market.

Key Takeaways

• Development has stalled with no recent active clinical trials.
• The drug has multiple unmet needs if efficacy can be proven.
• Market entry faces high barriers due to existing therapies’ efficacy and safety profiles.
• Peak sales could reach hundreds of millions if given regulatory approval and market acceptance.
• The overall outlook remains uncertain without additional clinical advancements.

FAQs

1. What is the primary therapeutic goal of Arbaclofen placarbil?
   It aims to serve as a sustained-release GABA_B receptor agonist for neurological and gastrointestinal conditions.

2. Has Arbaclofen placarbil received regulatory approval?
   No, it has not received approval from the FDA or EMA and remains investigational.

3. Why has development stalled?
   Clinical trials have shown inconsistent efficacy and safety signals, leading to strategic pauses or discontinuation by developers.

4. Could it succeed in the current market?
   Potentially, if new clinical data demonstrate significant efficacy over existing therapies; otherwise, barriers remain high.

5. What are the main competitors?
   For spasticity: baclofen; for alcohol dependence: naltrexone and acamprosate; for G.I. motility: prucalopride.

References

[1] ClinicalTrials.gov. Search for Arbaclofen placarbil. Accessed Jan 2023.

[2] FDA database. Summary of drug development statuses.

[3] Pharma licensing news archives. Development partnerships and discontinuations.